CAPR News and Press, Capricor Therapeutics Inc.

2026-06-24 12:38:33 ET More on Regenxbio, uniQure, etc. Moderna: Flu Vaccine Progress Is Only Part Of The Story Moderna: From Buy To Sell After 128.2% Surge (Rating Downgrade) Moderna: The Comeback Is Now In Full Swing uniQure prices upsized $225M public offe...

2026-06-24 08:01:10 ET More on healthcare stocks IXJ: Healthcare Sector Dashboard For June IHI: Pressured Consumers, Unclear Healthcare Policy, Weak Price Action AI Revolutionizing Biopharma: Faster, Better, Cheaper Weekly ETFs: Five of 11 sectors record...

2026-06-18 15:28:24 ET The last time I spoke about Biohaven ( BHVN ) it was with a Seeking Alpha article entitled " Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026 ." With respect to this article, I mentioned that the company had achieved a comp...

2026-06-17 14:35:09 ET More on Regenxbio, Capricor Therapeutics, Inc., etc. Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript Replimune: Modeling The Coin Flip Of FDA Approval Capricor: I Rate It A B...

2026-06-10 13:52:11 ET Capricor Therapeutics, Inc. (CAPR) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 10, 2026 10:00 AM EDT... Read the full article on Seeking Alpha For further details see: Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47...

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that senior management will participate in the following upcoming investor conferences. ...

2026-06-03 04:43:43 ET Every recent article on Seeking Alpha about Capricor ( CAPR ) is a Buy or a Hold - except that one Sell article from December. So I checked out the article, and I found the argument was not lazy. It raised the right issues that are needed to assess a late-...

2026-05-26 03:56:18 ET More on the top constituents of the Russell Microcap Index Definium Therapeutics: High-Stakes Data Readouts Poised To Validate Best-In-Class Potential Quantum-Si incorporated (QSI) Shareholder/Analyst Call Prepared Remarks Transcript Capricor T...

2026-05-15 00:15:02 ET Boobalan Pachaiyappan from Roth Capital issued a price target of $38.00 for CAPR on 2026-05-15 02:51:36. The adjusted price target was set to $38.00. At the time of the announcement, CAPR was trading at $29.81. The overall price target consensus is...

2026-05-14 23:15:02 ET Roth Capital analyst issues BUY recommendation for CAPR on May 15, 2026 02:51AM ET. The previous analyst recommendation was Buy. CAPR was trading at $29.81 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ana...